PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9300613-3	1997	A single subcutaneous administration of HAL (0.25 mg/kg), YM (0.1 mg/kg), or SUL (250 mg/kg) significantly reduced the basal CCK-LI in mPFC by 20-40%; a selective D1 antagonist, SCH (up to 1.0 mg/kg), had no effect on basal CCK-LI.	Sulpiride	77-80	cholecystokinin	Rattus norvegicus	125-128	
22981453-6	2012	When slices were preperfused with 100muM sulpiride, a selective dopamine D(2) receptor antagonist, the CCK-8 (0.01muM) effect on electrically stimulated ACh release was increased nearly 2-fold.	Sulpiride	41-50	cholecystokinin	Rattus norvegicus	103-106	
9300613-4	1997	However, the reduction of CCK-LI induced by MAP (20-40%) was abolished by the pretreatment with HAL (0.025 and 0.25 mg/kg), YM (0.01 and 0.1 mg/kg), or SCH (1.0 mg/kg), without being affected by SUL (up to 250 mg/kg).	Sulpiride	195-198	cholecystokinin	Rattus norvegicus	26-29	
9300613-3	1997	A single subcutaneous administration of HAL (0.25 mg/kg), YM (0.1 mg/kg), or SUL (250 mg/kg) significantly reduced the basal CCK-LI in mPFC by 20-40%; a selective D1 antagonist, SCH (up to 1.0 mg/kg), had no effect on basal CCK-LI.	Sulpiride	77-80	cholecystokinin	Rattus norvegicus	224-227	
2825061-3	1987	A single administration of haloperidol decreased the CCK-8 IR in the corpus striatum and that of racemic sulpiride significantly decreased the CCK-8 IR in the frontal cortex and the limbic system.	Sulpiride	105-114	cholecystokinin	Rattus norvegicus	143-146	
2825061-6	1987	After chronic administration of racemic sulpiride or methaphetamine, CCK-8 IR in various brain regions exhibited a tendency close to that of control.	Sulpiride	40-49	cholecystokinin	Rattus norvegicus	69-72	
2948613-3	1986	Addition of 10 microM of (-)-sulpiride, a specific D-2 DA receptor antagonist, blocked the inhibitory effect of 100 nM of LY-141865 on the release of CCK-LI.	Sulpiride	25-38	cholecystokinin	Rattus norvegicus	150-153